Healthcare AI companies with enterprise contracts command 14.1x forward ARR

Yanne Capital says healthcare AI companies with signed enterprise contracts above $2 million in annual contract value closed 2025 at a median 14.1x forward ARR, more than double the multiple for peers without anchor deals. The research points to enterprise commitments, not model quality alone, as the key pricing driver heading into 2026.

Why it matters: - Healthcare AI valuations are splitting into two markets: companies with large signed enterprise contracts and companies without them. - The gap affects fundraising, deal speed and term structure across growth-stage rounds. - Yanne Capital says the premium is likely to persist into 2026 as health systems, payers and drugmakers continue to shape buying decisions.

What happened: - Yanne Capital published a new research paper on healthcare AI pricing in the 2025 growth market. - Healthcare AI companies with at least one signed enterprise contract above $2 million in annual contract value closed 2025 at a median 14.1x forward ARR. - Healthcare AI peers without an anchor contract closed at 5.3x forward ARR. - The spread between the two groups widened to 8.8 turns in 2025 from 4.2 turns in 2023. - Yanne Capital said the anchor contract has become the single largest determinant of clearing multiple.

The details: - The segment-wide median for growth-stage healthcare AI was 9.2x forward ARR in 2025. - That compared with 4.5x for non-AI healthtech and 11.8x for horizontal generative AI infrastructure, according to PitchBook US Venture Deal Terms, Q4 2025. - Yanne Capital said the healthcare AI median masks a bimodal distribution based on whether a health system, payer or pharmaceutical buyer has committed budget. - Strategic LP participation in growth-stage healthcare AI rounds reached 38% in 2025, up from 11% in 2022 and 6% in 2020, according to NVCA Yearbook 2026. - Yanne Capital said strategic investors are increasingly co-investors in the same rounds where they also sign commercial agreements. - Median round duration for Series B and Series C healthcare AI financings with an anchor contract fell to 3.8 months in 2025 from 7.4 months in 2023. - Rounds without an anchor still took 7.4 months at the median. - Non-AI healthtech rounds at the same stage took 5.2 months at the median. - Liquidation preferences of 1.5x or higher appeared in 22% of 2025 healthcare AI growth-stage rounds. - Yanne Capital said that rate was roughly triple the incidence in non-healthcare AI rounds. - Clinical documentation and ambient scribe tools priced highest in 2025 at a median 12.8x forward ARR. - That subsegment captured $1.4 billion of the $4.2 billion in growth-stage healthcare AI capital deployed in 2025. - Revenue cycle and prior authorization automation cleared 8.4x forward ARR. - Drug discovery and clinical trial AI cleared 7.1x forward ARR.

Between the lines: - The report argues that healthcare AI buyers are paying for signed enterprise distribution more than for model architecture. - The presence of a strategic investor can make an anchor contract harder to dislodge, reinforcing the valuation premium. - Yanne Capital said founders now face one combined commercial-and-financing negotiation instead of two separate processes. - The firm also said investors are protecting downside with tougher terms even as headline multiples rise. - Clinical documentation appears to benefit most because it has the clearest enterprise contract evidence, the largest ACVs and the shortest sales cycles.

What's next: - Yanne Capital expects the anchor-contract premium to persist into 2026. - Founders raising next year will likely need durable contract evidence to access top-tier multiples. - Investors are expected to place more weight on contract durability than on model quality alone.

The bottom line: - In healthcare AI, the market is rewarding signed enterprise budget far more than technology alone.